Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLuciano J. CostaUniversity of Alabama at BirminghamKWKatja WeiselUniversität HamburgNDNiels W.C.J. van de DonkDutch Cancer Society

Discussion

Loading...

Member takes

Implication

Randomized trial shows improved progression-free survival in functional high-risk multiple myeloma, suggesting potential benefits of ciltacabtagene autoleucel.

Key Points

  • Ciltacabtagene autoleucel significantly improves progression-free survival in patients with functional high-risk multiple myeloma, indicating favorable treatment effects.
  • Median progression-free survival (PFS) after treatment with cilta-cel was longer compared to standard of care, with a hazard ratio of 0.26 (P<.0001).
  • Subgroup analysis from CARTITUDE-4 involved patients receiving second-line treatment, highlighting efficacy against a poor prognosis in functional high-risk multiple myeloma patients with 79 enrolled participants. 22 deaths occurred in this group, but overall safety profiles were similar between treatment regimens.

Cite This Study

Costa et al. (2024) studied this question.

synapsesocial.com/papers/68e669beb6db6435875f5fd7https://doi.org/10.1200/jco.2024.42.16_suppl.7504
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup.2024 · 1 citations
  2. 2P48 | LONG-TERM PROGRESSION-FREE SURVIVAL BENEFIT WITH CILTACABTAGENE AUTOLEUCEL IN STANDARD-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA2026
  3. 3Ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis.2026
  4. 4Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma2025 · 4 citations
  5. 5Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.2024 · 9 citations